ID   2fTGH
AC   CVCL_0115
SY   2FTGH; 2-fTGH
DR   BTO; BTO:0005765
DR   MCCL; MCC:0000007
DR   ECACC; 12021508
DR   Wikidata; Q54584472
DR   Ximbio; 151484
RX   PubMed=1837150;
RX   PubMed=1906577;
RX   PubMed=2513475;
CC   Characteristics: 2fTGH was derived from a HPRT negative subline of HT-1080. Expression of gpt is under the control of a IFN-alpha inducible IFI6 (6-16) promoter and is thus only expressed when IFN-alpha is present in the growth medium.
CC   Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; 6-TG).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Transfected with: UniProtKB; P0A9M5; E.coli gpt.
CC   Transfected with: UniProtKB; P00557; E.coli hygromycin-B 4-O-kinase (hph).
ST   Source(s): ECACC
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 12,14
ST   D16S539: 9,12
ST   D5S818: 11,13
ST   D7S820: 9,10
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 14,19
DI   NCIt; C3043; Fibrosarcoma
DI   ORDO; Orphanet_2030; Fibrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0317 ! HT-1080
SX   Male
AG   35Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 17
RX   PubMed=1837150; DOI=10.1073/pnas.88.24.11455;
RA   McKendry R., John J., Flavell D., Muller M., Kerr I.M., Stark G.R.;
RT   "High-frequency mutagenesis of human cells and characterization of a
RT   mutant unresponsive to both alpha and gamma interferons.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:11455-11459(1991).
RX   PubMed=1906577; DOI=10.1128/MCB.11.8.4189;
RA   John J., McKendry R., Pellegrini S., Flavell D., Kerr I.M.,
RA   Stark G.R.;
RT   "Isolation and characterization of a new mutant human cell line
RT   unresponsive to alpha and beta interferons.";
RL   Mol. Cell. Biol. 11:4189-4195(1991).
RX   PubMed=2513475; DOI=10.1128/MCB.9.11.4605;
RA   Pellegrini S., John J., Shearer M., Kerr I.M., Stark G.R.;
RT   "Use of a selectable marker regulated by alpha interferon to obtain
RT   mutations in the signaling pathway.";
RL   Mol. Cell. Biol. 9:4605-4612(1989).